Navigation Links
Miriam Hospital receives renewal of NIH grant for AIDS Clinical Trials Group
Date:3/19/2014

(PROVIDENCE, R.I.) A $2.4 million grant renewal will support The Miriam Hospital's continued efforts in research and new treatments for HIV and AIDS. The Miriam Hospital is the largest HIV/AIDS care provider in the state.

The ACTG is a global network of 60 research sites with its operations and laboratory center based at Brigham and Women's Hospital in Boston. The ACTG conducts clinical trials in HIV-infected adults to test novel therapeutic interventions focused on HIV-associated inflammation and resulting end-organ disease, tuberculosis, viral hepatitis and HIV cure.

Karen Tashima, M.D., the lead researcher at The Miriam, received the National Institutes of Health grant renewal. Tashima leads the ACTG's Providence site, which operates under the program's Harvard/Boston/Providence Clinical Trials Unit. She says, "We are thrilled with the results that have come from the ACTG Network. The Miriam Hospital has been part of the Network since 2000. Our work has allowed us to foster new investigations and treatments for treating HIV and AIDS."

Tashima says, "The ACTG is an important HIV clinical studies network that, for example, proved that mother to child transmission could be dramatically reduced by having the pregnant woman take the anti-HIV medication AZT. Results of other ACTG studies have changed how we treat HIV infection, and have resulted in Department of Health and Human Services HIV guideline changes leading to improvements nationally in the standard of care for HIV treatment."

Dr. Tashima was the lead investigator and study chair for the OPTIONS trial that was conducted at 64 sites across the continental U.S. and in Puerto Rico. The OPTIONS trial was a multi-site study that showed patients with drug-resistant HIV can safely achieve viral suppression the primary goal of HIV therapy without incorporating the traditional class of HIV medications into their treatment regimen. The ACTG trial showed for the first time that treatment-experienced patients can leave out this class of medication, known as nucleoside reverse transcriptase inhibitors (NRTI), as part of the regimen. Treatment-experienced patients already need to take three active medications in order to achieve viral suppression, so eliminating NRTI medications can lessen pill burden and side effects.

The Miriam Hospital is the largest care provider in Rhode Island, treating more than 1,500 patients with HIV who are under ongoing care. These patients have access to the latest treatments in HIV through our studies at The Immunology Center. Tashima says that she and other researchers in the ACTG look forward to more promising results coming from the research afforded by the grant renewal, which will allow The Miriam to continue to serve as an ACTG clinical research site for the 2014-2020 time period.


'/>"/>

Contact: Elena Falcone-Relvas
efalconerelvas@lifespan.org
401-793-7484
Lifespan
Source:Eurekalert

Related medicine news :

1. Miriam Hospital study shows social gaming site effective weight loss tool
2. Miriam Hospital study links intimate partner violence and risk of HIV
3. Miriam Hospital researcher awarded $2.9 million NIH grant to study impact of maternal smoking
4. Miriam researcher helps develop global hepatitis C recommendations for injection-drug users
5. Miriam study reveals financial benefits of a plant-based, Mediterranean diet
6. Miriam researchers urge physicians to ask younger men about erectile dysfunction symptoms
7. Smartphone app reads blood oxygen levels to hospital standards, advances to global obstetrics tests
8. Hospital food safety measures reduce risk of contaminated hospital food
9. One in 5 US hospitals dont put hand sanitizer everywhere needed to prevent infections
10. Better nurse staffing and education reduces patient deaths in European hospitals
11. Stand-alone facility for organ retrieval is more efficient, less costly than hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2019)... SCOTCH PLAINS, N.J. (PRWEB) , ... September 18, ... ... Michael L. Scagnelli, DMD for the fourth consecutive year. Dr. Scagnelli specializes in ... Matawan-based practice was established in the 1940’s and has been delivering quality dental ...
(Date:9/17/2019)... ... 17, 2019 , ... Six Consulting Inc. (SIX) recently announced ... – specifically golden retrievers - through innovative cancer prevention medicine. A national survey ... out of five retrievers in the United States will die from a particular ...
(Date:9/17/2019)... ... ... Lubin Austermuehle, P.C. will be one of the sponsors of GRIN2B ... Found Kitchen and Social House in Evanston on Monday, October 7 from 6 p.m. ... rare condition that results from changes to the GRIN2B gene. The GRIN2B gene is ...
(Date:9/17/2019)... LYNDHURST, N.J. (PRWEB) , ... September 17, 2019 ... ... in a wide array of services, welcomes Dr. Yevgeniya (Jenny) Gartshteyn to their ... University Medical Center, where she previously held the Clinical Appointment of Assistant Professor ...
(Date:9/11/2019)... ... September 12, 2019 , ... “Heart Seizures”: a useful source of ... disease as he hopes to prevent anyone from having it and to help those ... Saltwick, a writer who was diagnosed with coronary artery disease. Predicted to experience another ...
Breaking Medicine News(10 mins):
(Date:9/14/2019)... ... September 13, 2019 , ... St. Joseph’s Hospital, Robins ... the structural topping out of the St. Joseph’s Hospital patient tower expansion located ... new six-story patient tower that will house a two-story lobby, waiting and on-call ...
(Date:9/12/2019)... ... ... Stratosphere Networks will sponsor GRIN2B Foundation’s first cocktail reception fundraiser, ... at Found Kitchen and Social House in Evanston from 6 p.m. to 9 p.m. ... is a gene on the short arm of the 12th chromosome and is part ...
(Date:9/11/2019)... ... 12, 2019 , ... Understanding the Drug Supply Chain Security ... Sept. 26, 2019, 1:30-3:00 p.m. EDT, https://www.fdanews.com/understanding-the-dscsa , Need to comply ... clear on nuances of the guidelines regulating the drug supply chain? , ...
Breaking Medicine Technology: